Dark

Check out our Dark Pool Levels

ADOC
Edoc Acquisition Corp. Class A
stock NASDAQ

Inactive

Mar 21, 2024

2.85USD-64.464%(-5.17)589,811

Pre-market

0.00USD-100.000%(-8.02)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 6, 2022

12:00PM EST ADOCIA SA, a French socit anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today its financial calendar for 2022. GlobeNewswire Inc

Oct 14, 2021

01:30AM EDT -- This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in China -- First patient in the study will trigger a milestone payment to Adocia -- BC Lispro addresses the Chinese prandial insulin market which is approx. $1.4bn today with double-digit growth GlobeNewswire Inc

Sep 10, 2021

01:30AM EDT Adocia to Participate in the H.C. Wainwright 23rd Annual Global GlobeNewswire Inc

Jun 29, 2021

12:03PM EDT -- For the first time, a unique combination of two key hormones involved in glycemic control, a rapid acting insulin analog and an amylin analog, is tested in a single pump -- BioChaperone Lispro and Pramlintide coformulations safety, pharmacokinetic and glycemic control will be evaluated compared to insulin lispro GlobeNewswire Inc

Jun 15, 2021

01:30AM EDT ADOCIA Announces M1Pram Clinical Data Presentation at the American GlobeNewswire Inc

May 28, 2021

05:01PM EDT EDOC Acquisition Corp. Reports Regained Nasdaq Compliance Related To Delayed Annual Report Benzinga

May 26, 2021

01:30AM EDT Adocia Expands Clinical Development to Obesity with Patent GlobeNewswire Inc

Apr 22, 2021

05:28PM EDT Edoc Acquisition Reports Received Notice From Nasdaq Listing Department Related To Failure To File 10-K In Timely Fashion Benzinga

Share